Inc. () President and CEO Dr. Nader Pourhassan joined Steve Darling from Proactive Investors Vancouver on Skype to talk about encouraging news that the FDA will allow CytoDyn to submit on a rolling basis its planned Biologics License Application for Leronlimab. This is a humanized IgG4 mAb that is subcutaneously injected to block HIV-1 from entering and infecting immune cells.
Pourhassan told Proactive how rare this is for a company their size and when the first submissions will be made.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE
